89bio, Inc. (ETNB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Rohan Palekar
Employees:
40
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO, CA 94105
4155004614

89bio, Inc. focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21.

Data derived from most recent annual or quarterly report
Market Cap 757.157 Million Shares Outstanding46.537 Million Avg 30-day Volume 3.937 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue0.0 Debt to Equity0.154 EBITDA-88.182 Million
Price to Book Value2.0855 Operating Margin0.0 Enterprise Value131.338 Million
Current Ratio8.291 EPS Growth-0.455 Quick Ratio7.715
1 Yr BETA 0.3008 52-week High/Low 18.03 / 2.0 Profit Margin0.0
Operating Cash Flow Growth-66.0345 Altman Z-Score1.7135 Free Cash Flow to Firm -58.833 Million
Earnings Report2023-05-10
View SEC Filings from ETNB instead.

View recent insider trading info

89bio, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ETNB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ETNB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-03 by ATKINSON EDWARD MORROW III
  • 4: filed on 2023-02-22 by MANSBACH HARRY H
  • 4: filed on 2023-02-22 by MARTINS RYAN
  • 4: filed on 2023-02-22 by LE-NGUYEN QUOC
  • 4: filed on 2023-02-22 by PALEKAR ROHAN
  • 4: filed on 2023-02-13 by ALTSCHULER STEVEN
  • 4: filed on 2023-02-13 by MARTINS RYAN
  • 4: filed on 2023-02-13 by MANSBACH HARRY H
  • 4: filed on 2023-02-13 by PALEKAR ROHAN
  • 4: filed on 2023-02-13 by ZOTH LOTA S.

    • Events (8k)

  • 8-K: filed on 2023-03-22:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2023-02-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    17.6 Thousand total shares from 5 transactions

    Exercise Derivative Conversion (M)

    13 Thousand total shares from 2 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ATKINSON EDWARD MORROW III

    • Director
    		 0 2023-03-01 3

    MANSBACH HARRY H CHIEF MEDICAL OFFICER

    • Officer
    		 94,671 2023-02-17 7

    PALEKAR ROHAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 284,072 2023-02-17 5

    MARTINS RYAN CHIEF FINANCIAL OFFICER

    • Officer
    		 58,578 2023-02-17 8

    LE-NGUYEN QUOC SEE REMARKS

    • Officer
    		 91,179 2023-02-17 6

    LAPORTE KATHLEEN

    • Director
    		 0 2023-02-09 2

    ZOTH LOTA S.

    • Director
    		 0 2023-02-09 2

    HAYDEN MICHAEL R

    • Director
    		 0 2023-02-09 2

    ALTSCHULER STEVEN

    • Director
    		 0 2023-02-09 2

    GRUNBERG GREGORY

    • Director
    • 10% Owner
    		 0 2023-02-09 2

    DIROCCO DEREK

    • Director
    		 0 2023-02-09 2

    RA CAPITAL MANAGEMENT, L.P.

    RA CAPITAL HEALTHCARE FUND LP

    RA CAPITAL NEXUS FUND, L.P.

    KOLCHINSKY PETER

    SHAH RAJEEV M.

    • Director
    • 10% Owner
    		 8,955,410 2022-10-18 3

    WAISBOURD RAM SEE REMARKS

    • Officer
    		 33,750 2022-02-17 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    ORBIMED ADVISORS ISRAEL II LTD

    ORBIMED ISRAEL GP II, L.P.

    • 10% Owner
    		 7,339,220 2022-01-25 0

    RA CAPITAL MANAGEMENT, L.P.

    RA CAPITAL HEALTHCARE FUND LP

    KOLCHINSKY PETER

    SHAH RAJEEV M.

    • Director
    • 10% Owner
    		 4,965,769 2021-06-02 3

    NASCHITZ ANAT

    • Director
    • 10% Owner
    		 3,729,442 2021-04-15 0

    LONGITUDE CAPITAL PARTNERS III, LLC

    LONGITUDE VENTURE PARTNERS III, L.P.

    TAMMENOMS BAKKER JULIET

    ENRIGHT PATRICK G

    • 10% Owner
    		 No longer subject to file 2020-11-16 0

    KARIV TOMER

    PONTIFAX (ISRAEL) V, L.P.

    PONTIFAX (CAYMAN) V, L.P.

    PONTIFAX (CHINA) V, L.P.

    PONTIFAX 5 G.P. L.P.

    PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

    PONTIFAX LATE STAGE GP LTD.

    PONTIFAX LATE STAGE FUND L.P.

    • Director
    • 10% Owner
    		 1,134,671 2019-11-11 0

    KARIV TOMER

    PONTIFAX (ISRAEL) V, L.P.

    PONTIFAX (CAYMAN) V, L.P.

    PONTIFAX (CHINA) V, L.P.

    PONTIFAX 5 G.P. L.P.

    PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

    • Director
    • 10% Owner
    		 0 2019-11-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    ATKINSON EDWARD MORROW III - Director

    		2023-03-03 17:18:08 -0500 2023-03-01 M 10,000 d 20,000 direct

    ATKINSON EDWARD MORROW III - Director

    		2023-03-03 17:18:08 -0500 2023-03-01 S 10,000 $13.60 d 0 direct yes -7.0463 -10.1779 0.0 1 -14.5907 5

    ATKINSON EDWARD MORROW III - Director

    		2023-03-03 17:18:08 -0500 2023-03-01 M 10,000 $4.44 a 10,000 direct -7.0463 -10.1779 0.0 1 -14.5907 5

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-22 18:39:23 -0500 2023-02-21 S 2,540 $13.89 d 58,578 direct yes -4.003 -1.0378 3.2617 5 -4.003 2

    MANSBACH HARRY H - Officer CHIEF MEDICAL OFFICER

    		2023-02-22 18:41:51 -0500 2023-02-17 F 2,127 $13.97 d 94,671 direct -4.003 -1.0378 3.2617 5 -4.003 2

    PALEKAR ROHAN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-22 18:38:59 -0500 2023-02-17 F 6,279 $13.97 d 284,072 direct -4.003 -1.0378 3.2617 5 -4.003 2

    LE-NGUYEN QUOC - Officer SEE REMARKS

    		2023-02-22 18:39:19 -0500 2023-02-17 F 2,140 $13.97 d 91,179 direct -4.003 -1.0378 3.2617 5 -4.003 2

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-22 18:39:23 -0500 2023-02-17 F 1,750 $13.97 d 61,118 direct -4.003 -1.0378 3.2617 5 -4.003 2

    LE-NGUYEN QUOC - Officer SEE REMARKS

    		2023-02-13 17:37:22 -0500 2023-02-09 A 120,000 a 120,000 direct

    LE-NGUYEN QUOC - Officer SEE REMARKS

    		2023-02-13 17:37:22 -0500 2023-02-09 A 30,000 a 93,319 direct -3.4175 1.6345 3.789 4 -3.4175 2

    MANSBACH HARRY H - Officer CHIEF MEDICAL OFFICER

    		2023-02-13 17:42:52 -0500 2023-02-09 A 30,000 a 96,798 direct -3.4175 1.6345 3.789 4 -3.4175 2

    MANSBACH HARRY H - Officer CHIEF MEDICAL OFFICER

    		2023-02-13 17:42:52 -0500 2023-02-09 A 120,000 a 120,000 direct

    PALEKAR ROHAN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-13 17:42:41 -0500 2023-02-09 A 75,000 a 290,351 direct -3.4175 1.6345 3.789 4 -3.4175 2

    PALEKAR ROHAN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-13 17:42:41 -0500 2023-02-09 A 300,000 a 300,000 direct

    ZOTH LOTA S. - Director

    		2023-02-13 17:42:16 -0500 2023-02-09 A 27,400 a 27,400 direct

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-13 17:43:33 -0500 2023-02-09 A 30,000 a 62,868 direct -3.4175 1.6345 3.789 4 -3.4175 2

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-13 17:43:33 -0500 2023-02-09 A 110,000 a 110,000 direct

    ALTSCHULER STEVEN - Director

    		2023-02-13 17:48:01 -0500 2023-02-09 A 27,400 a 27,400 direct

    HAYDEN MICHAEL R - Director

    		2023-02-13 17:34:39 -0500 2023-02-09 A 27,400 a 27,400 direct

    GRUNBERG GREGORY - Director - > 10% Owner

    		2023-02-13 17:34:51 -0500 2023-02-09 A 27,400 a 27,400 direct

    LAPORTE KATHLEEN - Director

    		2023-02-13 17:35:31 -0500 2023-02-09 A 27,400 a 27,400 direct

    DIROCCO DEREK - Director

    		2023-02-13 17:30:19 -0500 2023-02-09 A 27,400 a 27,400 direct

    ATKINSON EDWARD MORROW III - Director

    		2023-02-13 17:33:20 -0500 2023-02-09 A 27,400 a 27,400 direct

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-10 17:32:38 -0500 2023-02-08 S 1,480 $14.41 d 32,868 direct yes -1.9665 1.1653 1.748 5 -5.3168 3

    MANSBACH HARRY H - Officer CHIEF MEDICAL OFFICER

    		2023-02-07 19:38:15 -0500 2023-02-05 F 1,360 $13.24 d 66,798 direct 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    LE-NGUYEN QUOC - Officer SEE REMARKS

    		2023-02-07 19:35:16 -0500 2023-02-05 F 1,390 $13.24 d 63,319 direct 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    PALEKAR ROHAN - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-02-07 19:36:17 -0500 2023-02-05 F 4,078 $13.24 d 215,351 direct 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 19:36:16 -0500 2023-02-05 F 592 $13.24 d 34,348 direct 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 19:36:16 -0500 2023-02-03 M 3,000 d 81,901 direct

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 19:36:16 -0500 2023-02-03 S 592 $12.70 d 35,368 direct yes 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 19:36:16 -0500 2023-02-03 M 3,000 $3.11 a 38,960 direct 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-07 19:36:16 -0500 2023-02-03 S 3,000 $13.11 d 38,960 direct yes 0.5472 -11.0807 15.8687 15.8687 31 -25.2394 29

    MARTINS RYAN - Officer CHIEF FINANCIAL OFFICER

    		2023-02-03 17:10:50 -0500 2023-02-01 F 408 $12.05 d 35,960 direct 0.9028 -4.6528 -24.0972 2.0833 4 -24.0972 31

    LE-NGUYEN QUOC - Officer SEE REMARKS

    		2023-02-03 17:08:17 -0500 2023-02-01 F 695 $12.05 d 64,709 direct 0.9028 -4.6528 -24.0972 2.0833 4 -24.0972 31

    MANSBACH HARRY H - Officer CHIEF MEDICAL OFFICER

    		2023-02-03 17:10:43 -0500 2023-02-01 F 680 $12.05 d 68,158 direct 0.9028 -4.6528 -24.0972 2.0833 4 -24.0972 31

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    89BIO INC ETNB 2023-03-24 22:15:03 UTC 3.308 1.512 600000
    89BIO INC ETNB 2023-03-24 21:45:03 UTC 3.2963 1.5237 600000
    89BIO INC ETNB 2023-03-24 21:15:03 UTC 3.2963 1.5237 600000
    89BIO INC ETNB 2023-03-24 20:45:03 UTC 3.3242 1.4958 600000
    89BIO INC ETNB 2023-03-24 20:15:04 UTC 3.3242 1.4958 600000
    89BIO INC ETNB 2023-03-24 19:45:03 UTC 3.3242 1.4958 650000
    89BIO INC ETNB 2023-03-24 19:15:04 UTC 3.3242 1.4958 650000
    89BIO INC ETNB 2023-03-24 18:45:04 UTC 2.8066 2.0134 650000
    89BIO INC ETNB 2023-03-24 18:15:03 UTC 2.8066 2.0134 650000
    89BIO INC ETNB 2023-03-24 17:45:03 UTC 2.8066 2.0134 650000
    89BIO INC ETNB 2023-03-24 17:15:03 UTC 2.8066 2.0134 700000
    89BIO INC ETNB 2023-03-24 16:45:03 UTC 2.8066 2.0134 700000
    89BIO INC ETNB 2023-03-24 16:15:03 UTC 2.8066 2.0134 450000
    89BIO INC ETNB 2023-03-24 15:45:03 UTC 1.566 3.254 450000
    89BIO INC ETNB 2023-03-24 15:15:03 UTC 1.566 3.254 700000
    89BIO INC ETNB 2023-03-24 14:45:03 UTC 2.7174 2.1026 700000
    89BIO INC ETNB 2023-03-24 14:15:03 UTC 2.7174 2.1026 450000
    89BIO INC ETNB 2023-03-24 13:45:03 UTC 3.2986 1.2714 450000
    89BIO INC ETNB 2023-03-24 13:15:04 UTC 3.2986 1.2714 450000
    89BIO INC ETNB 2023-03-24 12:45:03 UTC 3.2986 1.2714 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund ETNB -4.0 shares, $-101.0 2020-03-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments